Pub. Date : 2021 Jan
PMID : 32976869
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | BACKGROUND AND PURPOSE: This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. | Ralimetinib | mitogen-activated protein kinase 14 | Homo sapiens |
| 2 | CONCLUSION: This phase 1 trial is the first trial to study the combination of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. | Ralimetinib | mitogen-activated protein kinase 14 | Homo sapiens |